Professor Gerhard Pölzl presents data to support that the repetitive use of levosimendan is feasible and safe even in an outpatient setting. The LevoRep and LionHart studies show a clear trend in reduction in heart failure readmission and mortality and the international, randomised, control trial, LEODOR, is expected to provide clear evidence for the efficacy of levosimendan in reducing the number of hospital admissions and readmissions after an acute heart failure event.
Dr Josep Comin-Colét comments at the end of the video and talks about the aim of the intermittent ambulatory approach to levosimendan treatment being to keep patients with advanced heart failure in remission. He also comments on the factors that still need to be investigated which include the treatment regimen and the cumulative dose (in responders), which will be answered by the LEODOR study.
Josep Comin-Colét is Director of the Cardiology Department of the University Hospital Bellvitge in Barcelona, Spain. He is a member of of the Heart Failure Association of the European Society of Cardiology and Advisor to the Ministry of Health of the Government of Catalonia for organisation of care of patients with chronic cardiovascular conditions. He isAssociate Professor of Cardiology at the University of Barcelona and has published more than 150 articles international journals of medicine and cardiology. Dr Comin- Colét is a reviewer for several journals in cardiology in Europe and the United States and PI of several clinical trials and a researcher at IDIBELL.
Alternatively login via
Back to epgonline.org